Healthcare Industry News: fentanyl buccal tablet
News Release - March 6, 2008
inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.SOMERSET, N.J., March 6 (HSMN NewsFeed) -- inVentiv Selling Solutions, a division of inVentiv Health (Nasdaq: VTIV ) and the industry leader in outsourced sales teams to the pharmaceutical industry, announced today that it has signed a contract with Cephalon Inc. to provide a sales team to support Amrix, Cephalon's once-daily extended-release muscle relaxant. In connection with this deployment, the company will also provide a variety of complementary services to support the sales program.
In addition to representing Cephalon, inVentiv Selling Solutions will use the same sales team to detail other, yet-to-be-identified products in the primary care market.
"inVentiv has a relationship with Cephalon that spans several of our companies and divisions. We are thrilled to be expanding that relationship by providing a sales team to support Amrix," said Paul Mignon, President of inVentiv Selling Solutions. "We look forward to putting our experience and our therapeutic expertise to work on behalf of this important product."
"inVentiv has an impressive track record and they've demonstrated a great willingness to work with us to help us achieve our goals," said Michael S. Mulholland, Senior Vice President, U.S. Pharmaceutical Operations at Cephalon, Inc. "We are very pleased to be partnering with them on this initiative."
About Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.
The company's proprietary products in the United States include: PROVIGIL® (modafinil) Tablets [C-IV], FENTORA® (fentanyl buccal tablet) [C-II], TRISENOX® (arsenic trioxide) injection, AMRIX® (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL® (naltrexone for extended-release injectable suspension), GABITRIL® (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ® (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.
About inVentiv Health
inVentiv Health, Inc. (Nasdaq: VTIV ) is an insights-driven global healthcare leader that provides dynamic solutions to deliver customer and patient success. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. inVentiv Health's client roster is comprised of more than 325 leading pharmaceutical, biotech, life sciences and healthcare payor companies, including all top 20 global pharmaceutical manufacturers. For more information, visit www.inventivhealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
Source: inVentiv Health
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.